The Gastric Cancer Diagnostic Procedure Market is gaining significant momentum as healthcare systems worldwide prioritize early cancer detection, precision diagnostics, and improved patient outcomes. Gastric cancer remains one of the leading causes of cancer-related mortality globally, particularly in Asia-Pacific and parts of Europe. The increasing prevalence of risk factors such as Helicobacter pylori infection, unhealthy dietary habits, smoking, and aging populations has intensified the need for reliable and timely diagnostic procedures.

According to industry analysis, the gastric cancer diagnostic procedure market is expected to grow from US$ 1,307.96 million in 2022 to US$ 1,912.03 million by 2028, registering a compound annual growth rate (CAGR) of 6.5% from 2022 to 2028. This robust growth reflects rising awareness of gastric cancer screening, expanding access to advanced diagnostic technologies, and increased investments in oncology research and infrastructure.

Market Dynamics and Growth Drivers

One of the key drivers of the Gastric Cancer Diagnostic Procedure Market is the growing emphasis on early-stage diagnosis, which significantly improves survival rates. Advancements in endoscopic imaging, molecular diagnostics, and in-vitro diagnostic (IVD) technologies have transformed traditional diagnostic approaches into more accurate, less invasive, and faster procedures.

Additionally, the integration of multiplexing molecular diagnostics and immunoassays has enabled clinicians to detect multiple biomarkers simultaneously, enhancing diagnostic efficiency and precision. Government-led screening initiatives, particularly in high-incidence regions, along with the expansion of diagnostic laboratories and oncology specialty clinics, are further supporting market growth.

Market Segmentation Overview

By Healthcare Provider

Diagnostic Laboratories

Hospitals

Cancer Research Institutes

Oncology Specialty Clinics

By Symptom Type

Symptomatic and Asymptomatic

By Body Fluid

Blood

Urine

Saliva

Stomach Wash/Gastric Juice

Tissue

By Procedure

Endoscopic Procedures

Biopsy & Tissue Tests

Lab Tests

In-Vitro Diagnostic Tests

Imaging Tests

Molecular Diagnostics

Multiplexing Molecular Diagnostics & Immunoassays

Market Insights

Rise in Prevalence of Gastrointestinal Diseases

Despite declining incidence and mortality during the last decades, stomach cancer is perceived as one of the main health challenges worldwide. According to the GLOBOCAN, stomach cancer caused ~800,000 deaths (accounting for 7.7% of all cancer-related deaths) in 2020. The disease ranks as the fourth leading cause of cancer deaths in both genders combined. ~1.1 million new cases of stomach cancer were diagnosed in 2020, accounting for 5.6% of all cancer cases. Asia accounts for ~75% of the new stomach cancer cases and deaths reported globally. Western countries, such as the US and Canada, report high GI disease incidence rates, which can be attributed to increasing obesity in the adult population and less consumption of dietary fibers. According to data released by the Centers for Disease Control and Prevention in December 2022, physicians’ offices in the US record ~37.2 million cases of digestive system diseases.

Regional Insights

Geographically, Asia-Pacific holds a significant share of the Gastric Cancer Diagnostic Procedure Market due to high disease prevalence, well-established screening programs, and improving healthcare infrastructure in countries such as Japan, China, and South Korea. North America and Europe follow, supported by strong research ecosystems, advanced diagnostic adoption, and favorable reimbursement policies. Emerging economies are also expected to present lucrative opportunities as awareness and access to cancer diagnostics improve.

Competitive Landscape and Key Market Players-

Atlas-Link Biotech Co Ltd

Bio-Rad Laboratories Inc

MiRXES Pte Ltd

Agilent Technologies Inc

  1. Hoffmann-La Roche Ltd

bioMerieux SA

Thermo Fisher Scientific Inc

Illumina Inc

Vela Diagnostics Holding Pte Ltd

These companies are actively investing in advanced molecular assays, next-generation sequencing (NGS) solutions, and automated diagnostic platforms to strengthen their market position and address unmet clinical needs.

Future Outlook

The future of the Gastric Cancer Diagnostic Procedure Market is strongly aligned with the evolution of precision medicine and personalized oncology. Continuous advancements in molecular diagnostics, artificial intelligence-assisted imaging, and biomarker discovery are expected to redefine diagnostic accuracy and speed. As healthcare systems shift toward value-based care and preventive diagnostics, the demand for comprehensive gastric cancer diagnostic solutions will continue to rise.

In conclusion, the Gastric Cancer Diagnostic Procedure Market presents significant growth opportunities driven by technological innovation, expanding screening initiatives, and increasing global cancer burden. Stakeholders across diagnostics, healthcare providers, and research institutions are well-positioned to benefit from this evolving and high-impact market.

Related Reports:

Cancer Therapy Market - https://www.theinsightpartners.com/reports/cancer-therapy-market

Cancer Test Market - https://www.theinsightpartners.com/reports/cancer-test-market

Cervical Cancer Test Market - https://www.theinsightpartners.com/reports/cervical-cancer-test-market

Lung Cancer Surgery Market - https://www.theinsightpartners.com/reports/lung-cancer-surgery-market

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us: